Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260495 | 0.82 | ITGB3 (0.47) | TACR1MAPT | |
| SCHEMBL2521344 | 0.82 | ITGB3 (0.47) | TACR1MAPT | |
| SCHEMBL27552219 | 0.78 | TACR1 (0.61) | TACR1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL27478279 | 0.78 | TACR1 (0.61) | TACR1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL2528613 | 0.78 | KLK5 (0.46) | ALDH1A1MAPT | |
| SCHEMBL2528611 | 0.78 | KLK5 (0.46) | ALDH1A1MAPT | |
| SCHEMBL2530146 | 0.76 | ALDH1A1 (0.53) | ALDH1A1LMNAKMT2AMAPTMEN1 | |
| SCHEMBL8410995 | 0.76 | TACR1 (0.44) | TACR1ALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL6371364 | 0.75 | TACR1 (0.53) | TACR1ALDH1A1KMT2AMAPT | |
| SCHEMBL27478679 | 0.75 | TACR1 (0.53) | TACR1ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039455-B2 | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | US | disclosed |
| CN-101351455-A | Macrocyclic compounds useful as BACE inhibitors | NOVARTIS AG (CH) | 2009-01-21 | — | — | CN | disclosed |
| EP-1968954-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077004-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029960-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS | SLC10A2, SLC10A1, ASAH2 | TACR1 2992/4885ALDH1A1 2955/4885LMNA 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.